A 55-year-old female with standard risk AML in second CR received an allogenic transplant from an HLAmatched sibling, using a nonmyeloablative conditioning regimen (NMST). On day þ 139, she rejected her graft with autologous reconstitution. She received a second NMST from a different HLA-matched sibling with an identical conditioning regimen and immunosuppression. On day þ 110, she rejected the second graft, with autologous reconstitution with blasts. She received a third allograft from the first sibling with a myeloablative busulfan-based conditioning regimen. She is now day þ 270, in CR, with full donor chimerism. Older patients and those with medical contraindications to receiving a conventional allograft can benefit from a reduced intensity or a nonmyeloablative conditioning regimen (NMST) to relay a graft-versus-tumor (GVT) effect. Post graft immunosuppression is directed at preventing graft-versus-host disease (GVHD) and at overcoming host-versus-graft (HVG) reactions, reducing the need for an intensive immunosuppressive conditioning program. NMST seems to have less early morbidity and mortality, than is associated with conventional high-dose chemotherapy. 1, 7, 8 Case report
loablative allograft Allogenic stem cell transplantation (SCT) is an effective treatment for patients with hematological malignancies. [1] [2] [3] [4] [5] [6] Older patients and those with medical contraindications to receiving a conventional allograft can benefit from a reduced intensity or a nonmyeloablative conditioning regimen (NMST) to relay a graft-versus-tumor (GVT) effect. Post graft immunosuppression is directed at preventing graft-versus-host disease (GVHD) and at overcoming host-versus-graft (HVG) reactions, reducing the need for an intensive immunosuppressive conditioning program. NMST seems to have less early morbidity and mortality, than is associated with conventional high-dose chemotherapy. 1, 7, 8 Case report
A 55-year-old female with standard risk AML by cytogenetics, in second CR, received an allogenic stem cell transplant using an NMST. In our Center, patients X55 years old with AML in first or second CR, with a matched sibling donor, are offered an allogenic transplant using an NMST in an attempt to reduce regimen related toxicity. The conditioning regimen included fludarabine 30 mg/m 2 on days À4, À3 and À2, low-dose TBI (200 cGy) on day 0, and post grafting immunosuppression with a combination of mycofenolate mofetil (MMF) and cyclosporine (CSA). 1 The patient received a PBSC graft from a 61-year-old HLA-matched (matching was by serological analysis for HLA-A, -B, and -C, and by molecular matching for HLA-DRB1), ABO-matched male sibling donor, and 7.0 Â 10 6 unmanipulated CD34 þ cells/kg was infused. Donor chimerism was assessed among blood T cells, granulocytes, and unfractionated bone marrow by polymerasechain-reaction (PCR)-based analyses of variable numbers of tandem repeats. With these PCR tests, a minor population of DNA can be detected even when its concentration is as low as 1-5% of the total. 9 Day 28 donor chimerism assessment showed: donor T cells 75%; granulocytes 84%; and bone marrow 84%. Disease assessment showed complete remission. The patient developed grade II skin aGVHD on day þ 28. Day 56 donor chimerism assessment showed: donor T cells 70%, granulocytes 75%, and bone marrow 79%, and she was in CR. In the absence of aGVHD, CSA was tapered, starting on day þ 56. At day þ 73, she showed a decline in donor chimerism (donor CD3 compartment was 60% and granulocytes 63%), and cyclosporine was rapidly tapered off with no aGVHD flare. On day þ 95, donor T cells were 68%. On day þ 139, she had a rapid decline in white cell count (WCC) and platelet count (PLT). Bone marrow examination showed a hypoplastic bone marrow. Neither CMV nor HHV6 or Parvovirus was detected. The patient rejected the graft without peripheral blood donor T cells or granulocytes being detectable; no donor cells were found on unfractionated bone marrow analysis. No myeloid blasts were found in either bone marrow or peripheral blood by morphology or by flow cytometry analysis. The patient was admitted to the ward because of neutropenic fever. She was then allografted 155 days after her first NMST from a second 64-year-old HLA-matched, ABO-matched male sibling donor after G-CSF mobilization. Conditioning and post graft immunosuppression were the same as for the first transplant. A total of 2.58 Â 10 6 unmanipulated CD34 þ cells/kg was infused. The patient tolerated the second transplant well, with only a catheter-related infection, which promptly resolved on antibiotic treatment. Day 28 donor chimerism assessment showed: donor T cells 80%, granulocytes 90%, and bone marrow 90%. Disease assessment showed CR. She developed skin aGVHD grade II on day þ 32 post grafting. Day þ 56 chimerism showed donor T cells 75%, granulocytes 90%, and bone marrow 80%. In the absence of aGVHD, CSA was tapered on day þ 56, as per protocol. On day þ 100, she had a decline in WCC (total WCC 1500/ml) and PLT (45 000/ml) count, and a few days later she was admitted on the ward with fever and pancytopenia. An extensive work-up for viral infection on bone marrow and peripheral blood was performed, and HHV6 and Parvovirus were ruled out on bone marrow by PCR; CMV was ruled out on bone marrow by early antigenemia and shell vial cultures, and on peripheral blood by early antigenemia and by PCR amplification of viral DNA. Donor chimerism assessment showed a marked decrease in donor cells; in particular, T cells were 25% donor in the peripheral blood and no concurrent myeloid blasts were found either in peripheral blood or in the bone marrow by morphology and flow cytometry. In an attempt to reverse the graft rejection, CSA was quickly tapered off and she received DLI 1 Â 10 7 donor CD3 cells/kg, which were unsuccessful in interrupting the rejection process. Chimerism analysis on peripheral blood (T cell and granulocyte donor compartment) and unfractionated bone marrow showed rejection of the second allograft, with autologous reconstitution after a few weeks of aplasia. With the emergence of host hematopoiesis, myeloid blasts appeared with subsequent massive infiltration of the bone marrow. The patient received the third allograft 173 days from the second transplant from the first donor, with G-CSF mobilization. The patient received a regimen of intravenous fludarabine 30 mg/m 2 from day À9 to day À6, and oral busulfan, 1 mg/kg every 6 h Â 16 from day À5 to day À2; GVHD prophylaxis was with CSA and standard dose methotrexate, as described elsewhere. 10 She received 9.0 Â 10 6 CD34 þ cells/kg. Engraftment (4500 neutrophils/ml and 420 000 platelets/ml) was at days þ 17 and þ 16, respectively. The patient developed Pseudomonas aeruginosa sepsis, which resolved promptly with appropriate antibiotics, and grade IV mucositis. Analysis at day þ 28 showed full donor chimerism in all compartments, with CR of the disease. The patient experienced aGVHD of the skin grade II, but no VOD. She is now day þ 270 in CR, with full donor chimerism, and has developed extensive cGVHD (liver, eyes, mouth, skin), which is responding to immunosuppressive therapy.
Discussion
NMST causes reduced early morbidity and mortality 1, 2, 6 in patients otherwise ineligible for conventional allografting because of age or medical contraindications. This patient received a second NMST after rejection of the first allograft, emphasizing the safety and low toxicity of this regimen, and demonstrating that a second NMST from a different sibling, when available, might be an option in cases of rejection. With both rejections, there was autologous reconstitution, again demonstrating a lowregimen toxicity and nonfatal outcome. One, and even two consecutive NMST with this regimen, did not preclude a subsequent myeloablative allograft. A quick tapering of CSA and subsequent DLI was unable to reverse the rejection process, but a fludarabine/busulfan 10 regimen allowed engraftment in this patient. We conclude that flu/ low-dose TBI is a nonmyeloablative regimen, with low toxicity, allowing a second NMST. A myeloablative allograft was feasible after two NMST, and a flu/Bu regimen allowed engraftment. We can further speculate that intensification of the conditioning regimen, still maintaining potent immunosuppression, can play a role in the rescue of patients who reject a nonmyeloablative allograft, and in disease control. Moreover, there may be some patients for whom initial myeloablative SCT may be more effective both clinically and in terms of cost, but it may be difficult to identify these early.
